


Reticuline

Cat. No.:	HY-N1356												
CAS No.:	485-19-8												
Molecular Formula:	C ₁₉ H ₂₃ NO ₄												
Molecular Weight:	329.39												
Target:	JAK; STAT; NF-κB; Endogenous Metabolite												
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; NF-κB; Metabolic Enzyme/Protease												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (303.59 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.0359 mL	15.1796 mL	30.3591 mL
		5 mM	0.6072 mL	3.0359 mL	6.0718 mL
		10 mM	0.3036 mL	1.5180 mL	3.0359 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 ^[1] . Reticuline exhibits cardiovascular effects ^[2] .			
IC₅₀ & Target	JAK2	STAT3	NF-κB	Human Endogenous Metabolite
In Vitro	Reticuline (3 μM, 30 μM, 300 μM, 900 μM and 1.5 mM) inhibits in a concentration-dependent manner the contractions induced by Phenylephrine (1 μM), KCl (80 mM) and KCl (30 mM), (IC ₅₀ =40±10, 240±40 and 300±40 μM, respectively) in isolated			

rat aortic rings with intact endothelium^[2].

Reticuline (3 μ M, 30 μ M, 300 μ M, 900 μ M and 1.5 mM) antagonizes CaCl₂-induced contractions, and also inhibits the intracellular calcium dependent transient contractions induced by Norepinephrine (1 μ M), but not those induced by Caffeine (20 mM)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Reticuline (5, 10 and 20 mg/kg, i. v., randomly) injections produced an intense hypotension in normotensive rats. The hypotensive effect of Reticuline is probably due to a peripheral vasodilation in consequence of: 1) muscarinic stimulation and NOS activation in the vascular endothelium, 2) voltage-dependent Ca²⁺ channel blockade and/or 3) inhibition of Ca²⁺ release from norepinephrine-sensitive intracellular stores^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yang X, et al. Anti-Inflammatory Effects of Boldine and Reticuline Isolated from *Litsea cubeba* through JAK2/STAT3 and NF- κ B Signaling Pathways. *Planta Med.* 2018 Jan;84(1):20-25.

[2]. Katy LÍsias Dias, et al. Cardiovascular effects induced by reticuline in normotensive rats. *Planta Med.* 2004 Apr;70(4):328-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA